Form 4 for RYTM RHYTHM PHARMACEUTICALS, INC.
Accepted 2026-06-24 16:15:15 ET · period of report 2026-06-22 · accession 0001104659-26-077305 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| DT | 2026-06-24 16:15 | 2026-06-22 | RYTM | TETRAULT LYNN A. | Dir | M - OptEx | $28.27 | +37.0K | 44.0K | +529% | +$1.05M |
| DT | 2026-06-24 16:15 | 2026-06-22 | RYTM | TETRAULT LYNN A. | Dir | S - Sale+OE | $100.32 | -37.0K | 7,000 | -84% | -$3.71M |
| DT | 2026-06-24 16:15 | 2026-06-22 | RYTM | TETRAULT LYNN A. | Dir | M - OptEx | $0.00 | -37.0K | 0 | -100% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2026-06-22 | M | A | 37,000 | $28.27 | 44,000 | D | — | — | |
| 2 | Common | Common Stock | 2026-06-22 | S | D | 37,000 | $100.32 | 7,000 | D | — | — | (F1) The sales reported in the Form 4 were effected pursuant to a Rule 10b5-1 instruction adopted on December 15, 2025. (F2) The price reported is a weighted average price. The securities were sold in multiple transactions at per share prices ranging from $100.00 to $100.91. The Reporting Person undertakes to provide upon request the SEC staff, the Issuer, or any shareholder of the Issuer, full information regarding the number of securities sold at each separate price within the range set forth in this footnote. |
| 3 | Derivative | Stock Option (right to buy) | 2026-06-22 | M | D | 37,000 | $0.00 | 0 | D | $28.27 · — to 2030-12-08 | 37,000 Common Stock | (F3) The option is fully vested and exercisable. |